Phase 3 Readout

VOR: Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy

Name: Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy
Start: 2029-01-01
End: 2029-01-01

January 1, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2029
Company: Vor Biopharma Inc. (VOR)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy

January 1, 2029

VOR overview →

Company: Vor Biopharma Inc. (VOR)
Indication: Primary Sjogren's Disease